Taysha receives orphan drug designation from the european commission for tsha-102 for the treatment of rett syndrome

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced that it has been granted orphan drug designation from the european commission for tsha-102, an aav9-based gene replacement therapy in development for rett syndrome. “the rec
TSHA Ratings Summary
TSHA Quant Ranking